Cozen O’Connor: Amarin v. FDA Focuses the Spotlight on the First Amendment and the FDA's Regulation of Off-Label Promotion [Drug & Device Law]

Amarin v. FDA Focuses the Spotlight on the First Amendment and the FDA's Regulation of Off-Label Promotion [Drug & Device Law]

John Sullivan, a member of Cozen O'Connor's Commercial Litigation Department, discusses Amarin Pharma, Inc. v. FDA, in which Amarin seeks a declaration that the FDA's off-label regulations, as applied by the FDA, violate the First Amendment and the Due Process clause of the Fifth Amendment by failing to provide clarity on its position regarding off-label promotion.

To read the article, click here.


Related Attorneys

John J. Sullivan

Member

jsullivan@cozen.com

(212) 453-3729


Related Practices